A study by Toyoshima and colleagues developed models to predict the efficacy of peficitinib, a Janus kinase (JAK) inhibitor used for the treatment of RA, by examining its impact on ACR20 response rate and DAS28-CRP measurements in patients with RA [95]. Here, CRP is linked to rheumatoid arthritis.